Subgroup analysis shows improved progression-free survival in patients treated with durvalumab and TACE, indicating enhanced efficacy of TACE modalities.
Background: EMERALD-1 (NCT03778957) met its primary endpoint, showing improved progression-free survival (PFS) in pts with locoregional HCC treated with D+B+TACE versus PBO+TACE (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.98). This analysis assessed the impact of TACE modality (conventional TACE [cTACE] or drug-eluting bead [DEB]-TACE) on efficacy and safety outcomes.
No takes yet. Share an insight, caveat, or question.
Kröcher et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: